Overview

Study of Apremilast to Evaluate the Safety and Effectiveness for Patients With Rheumatoid Arthritis

Status:
Terminated
Trial end date:
2012-09-10
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether Apremilast is safe and effective in the treatment of patients with rheumatoid arthritis, specifically in improving signs and symptoms of rheumatoid arthritis (tender and swollen joints, pain, physical function and structure) in treated patients who have had an inadequate response to Methotrexate.
Phase:
Phase 2
Details
Lead Sponsor:
Amgen
Celgene Corporation
Treatments:
Apremilast
Thalidomide